Kwanan nan, JYMed Technology Co., Ltd. ya sanar da cewa Leuprorelin Acetate, wanda reshensa na Hubei JX Bio-Pharmaceutical Co., Ltd. ya samar, ya yi nasarar wuce binciken rajistar magunguna.
Bayanin Kasuwar Magunguna ta Asali
Leuprorelin Acetate magani ne na allura da ake amfani dashi don magance cututtukan da suka dogara da hormone, tare da tsarin kwayoyin C59H84N16O12•xC2H4O2. Yana da gonadotropin-sakin hormone agonist (GnRHa) wanda ke aiki ta hanyar hana tsarin pituitary-gonadadal. Asalin haɗin gwiwar AbbVie da Takeda Pharmaceutical, ana sayar da wannan magani a ƙarƙashin sunaye daban-daban a ƙasashe daban-daban. A {asar Amirka, ana sayar da shi a ƙarƙashin sunan LUPRON DEPOT, yayin da a China, ana sayar da shi a matsayin Yina Tong.
Tsara Tsara Tsari da Ingantattun Matsayi
Daga 2019 zuwa 2022, an kammala binciken harhada magunguna da haɓaka, sannan rajistar API a cikin Maris 2024, lokacin da aka karɓi sanarwar karɓa. An ƙaddamar da binciken rajistar miyagun ƙwayoyi a cikin watan Agusta 2024. JYMed Technology Co., Ltd. ke da alhakin haɓaka tsari, haɓaka hanyar nazari, nazarin ƙazanta, tabbatar da tsari, da kuma tabbatar da hanyar. Hubei JX Bio-Pharmaceutical Co., Ltd. shine ke kula da samar da ingantaccen tsari, ingantaccen hanyar nazari, da kuma nazarin kwanciyar hankali na API.
Fadada Kasuwa da Buƙatun Haɓaka
Haɓaka haɓakar ciwon daji na prostate da fibroids na mahaifa yana haifar da karuwar bukatar Leuprorelin Acetate. Kasuwar Arewacin Amurka a halin yanzu tana mamaye kasuwar Leuprorelin Acetate, tare da haɓaka kashe kuɗi na kiwon lafiya da kuma karɓar sabbin fasahohi sune manyan abubuwan haɓaka haɓaka. A lokaci guda, kasuwar Asiya, musamman Sin, tana kuma nuna buƙatu mai ƙarfi na Leuprorelin Acetate. Sakamakon tasirin sa, buƙatun duniya na wannan magani yana haɓaka, tare da girman kasuwa ana tsammanin ya kai dala miliyan 3,946.1 nan da 2031, yana nuna ƙimar haɓakar shekara-shekara (CAGR) na 4.86% daga 2021 zuwa 2031.
Game da JYMed
Shenzhen JYMed Technology Co., Ltd. (nan gaba ake magana a kai a matsayin JYMed) an kafa a 2009, ƙware a cikin bincike, ci gaba, samarwa, da kuma tallace-tallace na peptides da peptide alaka kayayyakin. Tare da cibiyar bincike guda ɗaya da manyan sansanonin samarwa guda uku, JYMed yana ɗaya daga cikin manyan masu samar da peptide API ɗin da aka haɗa ta sinadarai a cikin Sin. Babban ƙungiyar R&D na kamfanin yana alfahari sama da shekaru 20 na gogewa a cikin masana'antar peptide kuma ta sami nasarar wuce binciken FDA sau biyu. JYMed ta m da ingantaccen tsarin masana'antu peptide masana'antu yayi abokan ciniki cikakken kewayon ayyuka, ciki har da ci gaba da kuma samar da warkewa peptides, dabbobi peptides, antimicrobial peptides, da kwaskwarima peptides, kazalika da rajista da kuma kayyade goyon baya.
Babban Ayyukan Kasuwanci
1.Domestic da na duniya rajista na peptide APIs
2.Veterinary da na kwaskwarima peptides
3.Custom peptides da CRO, CMO, OEM ayyuka
4.PDC kwayoyi (peptide-radionuclide, peptide-kananan kwayoyin halitta, peptide-protein, peptide-RNA)
Baya ga Leuprorelin Acetate, JYMed ya ƙaddamar da takaddun rajista tare da FDA da CDE don wasu samfuran API da yawa, gami da shahararrun magungunan aji na GLP-1RA kamar Semaglutide, Liraglutide da Tirzepatide. Abokan ciniki na gaba masu amfani da samfuran JYMed za su iya yin la'akari kai tsaye lambar rajistar CDE ko lambar fayil ɗin DMF lokacin ƙaddamar da aikace-aikacen rajista ga FDA ko CDE. Wannan zai rage mahimmancin lokacin da ake buƙata don shirya takaddun aikace-aikacen, da kuma lokacin kimantawa da farashin bitar samfur.
Tuntube Mu
Shenzhen JYMed Technology Co., Ltd.
Adireshi:8th&9th Floors, Gine 1, Shenzhen Biomedical Innovation Industrial Park, No. 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen
Waya:+ 86 755-26612112
Yanar Gizo:http://www.jymedtech.com/
Lokacin aikawa: Agusta-29-2024